Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cervical Cancer clinical trials
73 of 151 indexed Cervical Cancer trials are currently recruiting.
151 US clinical trials · 73 currently recruiting
Cervical Cancer is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 73 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 78 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
The research picture
Cervical Cancer has 151 registered US clinical trials, 73 of them open to new participants right now, about 48% of the total.
- 73
- recruiting participants now
- 48%
- of trials open to enrollment
- 8
- in Phase 3–4 (later-stage)
- 11
- top sponsor: M.D. Anderson Cancer Center
Active & Recent Trials
151 total, page 2 of 4
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
NCT05512208
Image-Guided Gynecologic Brachytherapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02993900
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Memorial Sloan Kettering Cancer Center
NCT06925724
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen
NCT06157151
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04038619
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
NCT05475171
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
NCT04865887
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06315257
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
University Health Network, Toronto
NCT04016389
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Christian Hinrichs
NCT05483491
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
NCT06266338
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
UNC Lineberger Comprehensive Cancer Center
NCT04743674
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Abramson Cancer Center at Penn Medicine
NCT05758688
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
University of California, San Diego
NCT07121543
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT05686226
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University
NCT05838521
Detecting HPV DNA in Anal and Cervical Cancers
University of Chicago
NCT04857528
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
The University of Texas Health Science Center, Houston
NCT06082882
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics
NCT05812027
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics
NCT05973487
Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)
H. Lee Moffitt Cancer Center and Research Institute
NCT05645146
Sexual Health Empowerment for Women's Health
University of Kansas Medical Center
NCT03984695
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer
NCT03786081
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Agenus
NCT03894215
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06036121
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co.
NCT05438420
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
Baylor College of Medicine
NCT06577220
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Meghan Shea
NCT06238635
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co.
NCT04432857
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Cancer Institute (NCI)
NCT04287868
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT02285192
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Cancer Institute (NCI)
NCT04432597
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03614949
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
M.D. Anderson Cancer Center
NCT05047913
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
NCT05063916
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 30 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Cervical Cancer Trial Landscape
151 indexed Cervical Cancer studies · 73 recruiting (48%).
Phase mix: 8 late (III/IV) vs 78 early (I/II).
Top sponsor: M.D. Anderson Cancer Center (11 trials), 9 others listed. 50 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Cervical Cancer?
PlainTrial tracks 151 US clinical trials for Cervical Cancer, of which 73 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Cervical Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.